Updates are available Correction dated 2022-03-24
Click to view Correction: https://doi.org/10.1007/s40264-022-01167-2
-
Authors
Singh, Tina https://orcid.org/0000-0002-3930-7320
Delannois, Frédérique https://orcid.org/0000-0003-1247-2163
Haguinet, François https://orcid.org/0000-0003-4989-3738
Molo, Lifeter Yenwo
-
Funding
Funding for this research was provided by:
GlaxoSmithKline Biologicals SA
- License Information
-
More Information
Article History
Accepted: 13 December 2021
First Online: 11 January 2022
Change Date: 24 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40264-022-01167-2
Declarations
:
: This work was supported by GlaxoSmithKline Biologicals SA, which was the funding source and was involved in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA also took responsibility for all costs associated with the development and publishing of the present manuscript.
: Tina Singh, Frédérique Delannois, François Haguinet, and Lifeter Yenwo Molo are employees of the GSK group of companies. Frédérique Delannois, François Haguinet, and Tina Singh hold shares in the GSK group of companies as part of their employee remuneration. The authors declare no other financial or non-financial conflicts of interest.
: Not applicable.
: Not applicable.
: Not applicable.
: Rotarix is a trademark owned by the GSK group of companies; RotaTeq is a registered trademark of Merck & Co., Inc.; Rotavac is a registered trademark of Bharat Biotech; and Rotasiil is a registered trademark of the Serum Institute of India Ltd.
: The data that support the findings of this work are available from the corresponding author on reasonable request.
: Not applicable.
: All authors participated in the design, implementation, analysis and interpretation of the study, as well as the development of this manuscript. All authors had full access to the data and granted their final approval of the paper before submission.
